$ProShares Ultra Bloomberg Natural Gas(BOIL)$ Natural gas is so easy to trade! Supply barely moves all year round—just keep an eye on demand and weather! No long positions in spring and summer, no short positions in fall and winter. Stick to this rule, and steady profits are a given!
$NuScale Power(SMR)$ secures a $25B agreement with ENTRA1 Energy, a strong validation of its capability. While market attention was elsewhere, informed choices had spoken volumes. SMR is on a steady path, and its progress is worth watching.
$Palantir Technologies Inc.(PLTR)$ is on another surge! The stock broke through the 20-day moving average strongly—even more stable than NVIDIA lately. No need to gamble, just trust it.
$Direxion Daily S&P Biotech Bull 3x Shares(LABU)$ NAILED the biotech bounce with LABU! With FDA approvals speeding up and M&A heating up, taking some profits but keeping a moonbag - this sector's just getting started!
$Alibaba(BABA)$ is still solid—this rebound confirms my thesis. With strong fundamentals and dual focus on AI and e-commerce, I'm holding steady and waiting for value to shine through.
$Intel(INTC)$ Made a small profit, finally saw my years of technical analysis pay off. That moment of validation during the review? Totally worth it. The market may lie, but the charts never do.
$CTIHK(06055)$ It may not be flashy or headline-grabbing, but its roots run deep and its purpose is clear. This isn't a show pony，it’s a steady climber destined for a seat of power. With its pedigree and mandate, nothing else really needs to shine.
$Tencent Music(TME)$ Lately I’ve been feeling that music is not just for fun anymore，it’s moving into real healthcare. Tencent Music is killing it. With over 40 million licensed tracks and solid social + live-streaming features, it’s way more than just a music app. Now they’re even trying AI music therapy like healing through tunes, how wild is that? Ma Huateng’s reputation is solid, no big scandals, and their business keeps growing. By 2025, both revenue and profits are expected to keep climbing, and margins are improving too. Honestly, a company that lets people sing and make money? I’m holding tight.
$CARSGEN-B(02171)$ is accelerating its focus on off-the-shelf CAR-T cell therapy, with a subsidiary valued at an impressive 1 billion RMB. The company’s first commercialized product, Zevorcabtagene Autoleucel, has generated 39.4 million RMB in sales, and an application for the world’s first CAR-T therapy targeting solid tumors is set to be submitted in the first half of the year. This marks a crucial milestone for the company and could be a game-changer in the industry. Investors should keep a close eye on CARsgen’s R&D progress—its innovations hold great promise!